|
|||||
|
 | |
| |
| |
| |
| |
| |
|
Gene: GPATCH8 |
Gene summary for GPATCH8 |
 Gene summary. |
| Gene information | Species | Human | Gene symbol | GPATCH8 | Gene ID | 23131 |
| Gene name | G-patch domain containing 8 | |
| Gene Alias | GPATC8 | |
| Cytomap | 17q21.31 | |
| Gene Type | protein-coding | GO ID | GO:0008150 | UniProtAcc | Q9UKJ3 |
Top |
Malignant transformation analysis |
| Identification of the aberrant gene expression in precancerous and cancerous lesions by comparing the gene expression of stem-like cells in diseased tissues with normal stem cells |
| Malignant transformation involving gene list. |
| Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
| 23131 | GPATCH8 | CCI_1 | Human | Cervix | CC | 9.02e-06 | 7.38e-01 | 0.528 |
| 23131 | GPATCH8 | CCI_2 | Human | Cervix | CC | 1.38e-03 | 8.24e-01 | 0.5249 |
| 23131 | GPATCH8 | CCI_3 | Human | Cervix | CC | 5.04e-18 | 1.31e+00 | 0.516 |
| 23131 | GPATCH8 | HTA11_3410_2000001011 | Human | Colorectum | AD | 3.74e-03 | -3.55e-01 | 0.0155 |
| 23131 | GPATCH8 | HTA11_347_2000001011 | Human | Colorectum | AD | 9.64e-09 | 4.73e-01 | -0.1954 |
| 23131 | GPATCH8 | HTA11_411_2000001011 | Human | Colorectum | SER | 4.38e-02 | 5.73e-01 | -0.2602 |
| 23131 | GPATCH8 | HTA11_7862_2000001011 | Human | Colorectum | AD | 1.36e-02 | -3.34e-01 | -0.0179 |
| 23131 | GPATCH8 | HTA11_6818_2000001021 | Human | Colorectum | AD | 1.79e-02 | -3.76e-01 | 0.0588 |
| 23131 | GPATCH8 | HTA11_99999965062_69753 | Human | Colorectum | MSI-H | 5.83e-04 | 6.76e-01 | 0.3487 |
| 23131 | GPATCH8 | HTA11_99999965104_69814 | Human | Colorectum | MSS | 7.03e-11 | 7.39e-01 | 0.281 |
| 23131 | GPATCH8 | A001-C-207 | Human | Colorectum | FAP | 6.10e-04 | -1.95e-01 | 0.1278 |
| 23131 | GPATCH8 | A015-C-203 | Human | Colorectum | FAP | 8.31e-35 | -4.37e-01 | -0.1294 |
| 23131 | GPATCH8 | A015-C-204 | Human | Colorectum | FAP | 8.35e-07 | -3.22e-01 | -0.0228 |
| 23131 | GPATCH8 | A014-C-040 | Human | Colorectum | FAP | 2.38e-07 | -3.89e-01 | -0.1184 |
| 23131 | GPATCH8 | A002-C-201 | Human | Colorectum | FAP | 3.06e-16 | -3.53e-01 | 0.0324 |
| 23131 | GPATCH8 | A002-C-203 | Human | Colorectum | FAP | 1.33e-02 | -1.05e-01 | 0.2786 |
| 23131 | GPATCH8 | A001-C-119 | Human | Colorectum | FAP | 4.77e-07 | -2.15e-01 | -0.1557 |
| 23131 | GPATCH8 | A001-C-108 | Human | Colorectum | FAP | 1.48e-19 | -2.98e-01 | -0.0272 |
| 23131 | GPATCH8 | A002-C-205 | Human | Colorectum | FAP | 6.08e-29 | -4.61e-01 | -0.1236 |
| 23131 | GPATCH8 | A001-C-104 | Human | Colorectum | FAP | 4.12e-03 | -1.62e-01 | 0.0184 |
| Page: 1 2 3 4 5 6 7 8 9 10 |
| Transcriptomic changes along malignancy continuum. |
| Tissue | Expression Dynamics | Abbreviation |
| Cervix |  | CC: Cervix cancer |
| HSIL_HPV: HPV-infected high-grade squamous intraepithelial lesions | ||
| N_HPV: HPV-infected normal cervix | ||
| Colorectum (GSE201348) |  | FAP: Familial adenomatous polyposis |
| CRC: Colorectal cancer | ||
| Colorectum (HTA11) |  | AD: Adenomas |
| SER: Sessile serrated lesions | ||
| MSI-H: Microsatellite-high colorectal cancer | ||
| MSS: Microsatellite stable colorectal cancer | ||
| Esophagus |  | ESCC: Esophageal squamous cell carcinoma |
| HGIN: High-grade intraepithelial neoplasias | ||
| LGIN: Low-grade intraepithelial neoplasias | ||
| Liver |  | HCC: Hepatocellular carcinoma |
| NAFLD: Non-alcoholic fatty liver disease | ||
| Lung |  | AAH: Atypical adenomatous hyperplasia |
| AIS: Adenocarcinoma in situ | ||
| IAC: Invasive lung adenocarcinoma | ||
| MIA: Minimally invasive adenocarcinoma | ||
| Oral Cavity |  | EOLP: Erosive Oral lichen planus |
| LP: leukoplakia | ||
| NEOLP: Non-erosive oral lichen planus | ||
| OSCC: Oral squamous cell carcinoma | ||
| Prostate |  | BPH: Benign Prostatic Hyperplasia |
| Skin |  | AK: Actinic keratosis |
| cSCC: Cutaneous squamous cell carcinoma | ||
| SCCIS:squamous cell carcinoma in situ | ||
| Thyroid |  | ATC: Anaplastic thyroid cancer |
| HT: Hashimoto's thyroiditis | ||
| PTC: Papillary thyroid cancer |
| ∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
| Find out the enriched GO biological processes and KEGG pathways involved in transition from healthy to precancer to cancer |
| Figure of enriched GO biological processes. |
| Tissue | Disease Stage | Enriched GO biological Processes |
| Colorectum | AD |  |
| Colorectum | SER |  |
| Colorectum | MSS |  |
| Colorectum | MSI-H |  |
| Colorectum | FAP |  |
| ∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
| Page: 1 2 3 4 5 6 7 8 9 |
| Enriched GO biological processes. |
| GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
| Page: 1 |
| Enriched KEGG pathways. |
| Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
| Page: 1 |
Top |
Cell-cell communication analysis |
| Identification of potential cell-cell interactions between two cell types and their ligand-receptor pairs for different disease states |
| Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
| Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
| Find out the significant the regulons (TFs) and the target genes of each regulon across cell types for different disease states |
| TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
| ∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
| Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
| Annotation of somatic variants for genes involved in malignant transformation |
| Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
| GPATCH8 | insertion | Frame_Shift_Ins | novel | c.833_834insCTTCCCAGTTTTGAGCAAAGATGAA | p.Leu278PhefsTer19 | p.L278Ffs*19 | Q9UKJ3 | protein_coding | TCGA-A8-A095-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | 5-fluorouracil | CR | ||
| GPATCH8 | insertion | Frame_Shift_Ins | novel | c.806_807insAACTCTTCTAAAGAAACCTCTCTGGCCACCCCAG | p.Gly271LeufsTer29 | p.G271Lfs*29 | Q9UKJ3 | protein_coding | TCGA-AN-A0FX-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Unknown | Unknown | SD | ||
| GPATCH8 | insertion | In_Frame_Ins | novel | c.1928_1929insTTC | p.Asn643_Lys644insSer | p.N643_K644insS | Q9UKJ3 | protein_coding | TCGA-AO-A0J9-01 | Breast | breast invasive carcinoma | Female | <65 | III/IV | Chemotherapy | cyclophosphamide | PD | ||
| GPATCH8 | insertion | Frame_Shift_Ins | novel | c.1927_1928insGGAGAGGCATTCTGGGCGTCGGGACTTC | p.Asn643ArgfsTer17 | p.N643Rfs*17 | Q9UKJ3 | protein_coding | TCGA-AO-A0J9-01 | Breast | breast invasive carcinoma | Female | <65 | III/IV | Chemotherapy | cyclophosphamide | PD | ||
| GPATCH8 | insertion | Frame_Shift_Ins | novel | c.884_885insCATACCAGAGAGCGCTCAAGATCCCGGG | p.Leu295PhefsTer44 | p.L295Ffs*44 | Q9UKJ3 | protein_coding | TCGA-AO-A0JD-01 | Breast | breast invasive carcinoma | Female | <65 | III/IV | Chemotherapy | cyclophosphamide | SD | ||
| GPATCH8 | deletion | Frame_Shift_Del | c.4430delN | p.Thr1477MetfsTer42 | p.T1477Mfs*42 | Q9UKJ3 | protein_coding | TCGA-D8-A27V-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Hormone Therapy | tamoxiphen | SD | |||
| GPATCH8 | SNV | Missense_Mutation | novel | c.479A>T | p.His160Leu | p.H160L | Q9UKJ3 | protein_coding | deleterious(0) | probably_damaging(0.999) | TCGA-C5-A3HD-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Chemotherapy | cisplatin | SD |
| GPATCH8 | SNV | Missense_Mutation | novel | c.197N>A | p.Arg66Lys | p.R66K | Q9UKJ3 | protein_coding | deleterious_low_confidence(0) | probably_damaging(0.994) | TCGA-C5-A8XK-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Chemotherapy | cisplatin | SD |
| GPATCH8 | SNV | Missense_Mutation | c.3579N>G | p.Phe1193Leu | p.F1193L | Q9UKJ3 | protein_coding | tolerated(0.65) | benign(0) | TCGA-IR-A3LA-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Chemotherapy | cisplatin | CR | |
| GPATCH8 | SNV | Missense_Mutation | c.937N>A | p.Glu313Lys | p.E313K | Q9UKJ3 | protein_coding | deleterious(0) | possibly_damaging(0.825) | TCGA-Q1-A73O-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Chemotherapy | cisplatin | CR |
| Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 |
Top |
Related drugs of malignant transformation related genes |
| Identification of chemicals and drugs interact with genes involved in malignant transfromation |
| (DGIdb 4.0) |
| Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
| Page: 1 |
Copyright 2023-Present -The University of Texas Health Science Center at Houston |